Have a feature idea you'd love to see implemented?
Let us know!
FOLD Amicus Therapeutics Inc
Price (delayed)
$9.8
Market cap
$2.93B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.34
Enterprise value
$3.14B
Amicus Therapeutics is a global, patient-dedicated biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare metabolic diseases. With extraordinary patient focus, Amicus Therapeutics
Highlights
The EPS has grown by 42% YoY and by 13% from the previous quarter
The net income rose by 40% YoY and by 12% QoQ
Key stats
What are the main financial stats of FOLD
Market
Valuations
Earnings
Shares outstanding
298.81M
Market cap
$2.93B
Enterprise value
$3.14B
Price to earnings (P/E)
N/A
Price to book (P/B)
16.25
Price to sales (P/S)
6.05
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
6.36
Revenue
$493.67M
Gross profit
$444.24M
Net income
-$104.69M
EBIT
-$17.88M
EBITDA
-$9.2M
Free cash flow
-$31.51M
Per share
Balance sheet
Liquidity
EPS
-$0.34
EPS diluted
-$0.34
Free cash flow per share
-$0.1
Book value per share
$0.6
Revenue per share
$1.62
TBVPS
$1.87
Total assets
$786.56M
Total liabilities
$607.73M
Debt
$444.66M
Equity
$178.83M
Working capital
$340.34M
Debt to equity
2.49
Current ratio
3.15
Quick ratio
2.2
Net debt/EBITDA
-22.95
Margins
Efficiency
Dividend
EBITDA margin
-1.9%
Gross margin
90%
Net margin
-21.2%
Operating margin
-0.7%
Return on assets
-13.8%
Return on equity
-69.5%
Return on invested capital
-3%
Return on capital employed
-2.8%
Return on sales
-3.6%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
FOLD stock price
How has the Amicus Therapeutics stock price performed over time
Intraday
0.72%
1 week
4.7%
1 month
2.19%
1 year
-23.68%
YTD
-30.94%
QTD
-8.24%
Financial performance
How have Amicus Therapeutics's revenue and profit performed over time
Revenue
$493.67M
Gross profit
$444.24M
Operating income
-$3.47M
Net income
-$104.69M
Gross margin
90%
Net margin
-21.2%
The operating margin has soared by 98% YoY and by 92% QoQ
Amicus Therapeutics's operating income has surged by 97% YoY and by 91% QoQ
FOLD's net margin has surged by 55% year-on-year and by 19% since the previous quarter
The net income rose by 40% YoY and by 12% QoQ
Growth
What is Amicus Therapeutics's growth rate over time
Valuation
What is Amicus Therapeutics stock price valuation
P/E
N/A
P/B
16.25
P/S
6.05
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
6.36
The EPS has grown by 42% YoY and by 13% from the previous quarter
The equity has grown by 35% from the previous quarter and by 34% YoY
The P/B is 30% below the last 4 quarters average of 23.1 and 8% below the 5-year quarterly average of 17.7
FOLD's price to sales (P/S) is 44% lower than its 5-year quarterly average of 10.9 and 24% lower than its last 4 quarters average of 8.0
FOLD's revenue is up by 33% year-on-year and by 8% since the previous quarter
Efficiency
How efficient is Amicus Therapeutics business performance
The ROS has soared by 90% YoY and by 67% from the previous quarter
The ROIC has soared by 87% YoY and by 64% from the previous quarter
Amicus Therapeutics's return on equity has surged by 53% YoY and by 19% QoQ
FOLD's ROA is up by 42% YoY and by 13% from the previous quarter
Dividends
What is FOLD's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for FOLD.
Financial health
How did Amicus Therapeutics financials performed over time
FOLD's total assets is 29% greater than its total liabilities
FOLD's current ratio is up by 15% year-on-year and by 15% since the previous quarter
Amicus Therapeutics's quick ratio has increased by 7% from the previous quarter and by 5% YoY
FOLD's debt is 149% greater than its equity
The equity has grown by 35% from the previous quarter and by 34% YoY
FOLD's debt to equity is down by 27% YoY and by 26% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.